Our newest database – Beacon Biomarkers & Assays
Biomarkers are a vital tool to successfully treat patients and ensure they receive the most effective and cost-efficient treatment strategies. Accurate detection and measurement of these biomarkers is therefore essential and has driven the growth of the assay development space.
The ever-expanding assay and biomarker preclinical and clinical landscape is becoming increasingly difficult to search, track and benchmark. To combat this, Beacon is releasing it’s first standalone database since 2014 – Biomarkers & Assays. This independent database tackles these challenges in one comprehensive solution allowing you to find the information you need and focus on advancing your research.
Beacon Biomarkers & Assays
Our first of its kind database delivers the most complete biomarkers, assays and clinical trial landscape for lung cancer
What we cover
Our inaugural Beacon Biomarkers & Assays offering focuses on lung cancer, covering all biomarkers, assays and clinical trials investigating targeted therapies within the lung cancer landscape.
From preclinical validation of biomarkers and assays to regulatory interactions and updates to clinical trial data, this module encapsulates everything you need to know about the lung cancer biomarker and assay space.
How Beacon helps
Advance your lung cancer biomarker and assay development programs by:
- Understanding and benchmarking the different biomarker strategies used in clinical trials and the various assays and associated protocols used to measure these biomarkers.
- Scour the lung cancer landscape for novel or established biomarkers and assays and investigate the associated preclinical validation studies.
- Track developments across the regulatory landscape for lung cancer biomarkers and assays.
- Stay on top of emerging trends and new developments with real-time updates and alerts, as well as in-depth monthly reports curated by our analyst team.
How Biomarkers & Assays works
Search the biomarker, assay and trial landscape by over 30 unique properties including:
- Biomarker biology and classification
- Assay platform technology
- Regulatory status
- Drug target and therapeutic class
- Disease stage and line of therapy
Customize your search strategy to give you the data you need for your research focus.
How we target the data
We house all publicly available sources of data updated with 24 – 48 hours of publication proactively. Our sources cover (but are not limited to):
- Clinical trials registries
- Scientific journals and publications
- Company reports and presentations
- Press releases
- Conference reports and abstracts
- Government and regulatory organizations
- Assay developer websites and assay documentation
What our customers say
“[Biomarkers & Assays] is going to be a blockbuster in my opinion. It’s very valuable. There's no doubt about it… If I can delve into this information sooner rather than later before we write protocols and such, it's going to be amazing”
Senior Vice President
Multinational Biopharmaceutical Company
Our Biomarkers & Assays Expert
Dasha Kaloujskaia, is the lead research analyst for Biomarkers & Assays related trials and assays in the Beacon team.
Interested in a tour? Contact us
For a tour of the Beacon Biomarkers & Assays database, please contact the team below.
About Beacon
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Other Beacon Solutions
Covering all engineered and non-engineered immune cell therapies, including CAR-T, TCR, NK, TILs, Gamma-Delta T Cells and more
Covering all Bi- and Multi-Specific Antibodies, Antibody Fragments, Augmented Antibodies and more
Beacon Cancer Vaccine provides the solution you need to master the prophylactic and therapeutic cancer vaccines field.
Covering all Immune Checkpoint Combination Trials and Immune Checkpoint Modulators in development across 27 different checkpoint targets
Covering all cytokines and drugs that target a cytokine or its immediate receptor belonging to the Interleukins, Interferons, Colony-stimulating factors, Transforming growth factor β, Tumour necrosis factor and Chemokines families.
Beacon DDR steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the DDR field.
From gene-editing technologies, novel delivery systems, and a variety of genetic materials being used- Beacon Gene Therapy steps into the field to give drug developers a precise and detailed view of how the gene therapy landscape looks.
Covering all therapeutics aimed at treating immune-mediated diseases – Beacon Immune Tolerance provides drug developers with detailed views of the expanding immune tolerance landscape.
Covering all pharmaceutical grade microbiome-based therapeutics across all disease indications – Beacon Microbiome provides drug developers with detailed views of the expanding microbiome landscape.
From capturing viral family and strains to understanding any genetic modifications – Beacon Oncolytic Viruses steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the Oncolytic Virus field.
Covering Oligonucleotide-based, mRNA-Based, Ribozyme, and gRNA-Mediated Gene Editing therapies, as well as RNA-Targeted Small Molecules – Beacon RNA covers all disease indications and many modalities to provide a detailed landscape of the RNA space.
Beacon TPD provides the solution you need to master the targeted protein degradation field.
